|1.||Montemurro, F: 1 article (08/2007)|
|2.||Catalano, G: 1 article (08/2007)|
|3.||Di Martino, N: 1 article (08/2007)|
|4.||Orditura, M: 1 article (08/2007)|
|5.||Galizia, G: 1 article (08/2007)|
|6.||Ciardiello, F: 1 article (08/2007)|
|7.||Giuliani, F: 1 article (08/2007)|
|8.||Cartenì, G: 1 article (08/2007)|
|9.||Colucci, G: 1 article (08/2007)|
|10.||Gruppo Oncologico Italia Meridionale: 1 article (08/2007)|
|1.||Stomach Neoplasms (Stomach Cancer)
08/01/2007 - "In radically resected gastric cancer patients, adjuvant chemotherapy with ELFE regimen does not improve OS over surgery alone."
08/01/2007 - "This randomized, multicenter, phase III trial evaluated the efficacy and safety of the combination of epirubicin, leucovorin, 5-fluorouracil and etoposide (ELFE regimen) as adjuvant therapy for radically resected gastric cancer patients. "
06/01/1999 - "Furthermore, considering the good efficacy and mild toxicity observed with the addition of etoposide to the FA-FU combination in the German study, the authors conducted a trial to explore the efficacy and tolerability of the ELFE regimen (epirubicin, folinic acid, fluorouracil, and etoposide) in previously untreated advanced gastric cancer patients. "
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
|3.||Etoposide (VP 16)
|4.||Leucovorin (Folinic Acid)